News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Jame Abraham Highlighted NEJM Study on Inavolisib Combo in PIK3CA-Mutated Advanced Breast Cancer
Jame Abraham/my.clevelandclinic.org
Jun 1, 2025, 16:06

Jame Abraham Highlighted NEJM Study on Inavolisib Combo in PIK3CA-Mutated Advanced Breast Cancer

Jame Abraham, Chairman and Professor of the Department of Hematology and Medical Oncology at the Cleveland Clinic, shared a post on LinkedIn:

“A study on the treatment of PIK3CA-mutated advanced breast cancer revealed promising results. The combination of inavolisib with palbociclib-fulvestrant showed a notable improvement in overall survival compared to the placebo-palbociclib-fulvestrant combination.
However, it is important to note that certain side effects such as hyperglycemia, stomatitis or mucosal inflammation, gastrointestinal, and ocular toxic effects were more commonly observed with inavolisib. This study sheds light on the potential benefits and risks associated with this treatment approach.”

Breast Cancer

Title: Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer

Journal: NEJM

Authors: Komal L. Jhaveri, Seock-Ah Im, Cristina Saura, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Eirini Thanopoulou, Noopur Shankar, Yanling Jin, Thomas J. Stout, Tiffany D. Clark, Chunyan Song, Dejan Juric, Nicholas C. Turner

Read the full article.

Breast Cancer

More posts featuring Jame Abraham on OncoDaily.

Breast Cancer cancer Chunyan Song Cleveland Clinic Cristina Saura Dejan Juric Eirini Thanopoulou Fulvestrant Inavolisib Jame Abraham Kevin Kalinsky Komal L. Jhaveri NEJM Nicholas C. Turner Noopur Shankar OncoDaily Oncology palbociclib Peter Schmid PIK3CA-mutated breast cancer Seock-Ah Im Sherene Loi Sibylle Loibl Thomas J Stout Tiffany D. Clark Yanling Jin
Special Coverage
Blog
Jun 23, 2025, 18:55
Elvina Almuradova: What Comes After CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer?
Blog
Jun 23, 2025, 18:11
Wafaa M Rashed: The Countdown Begins for Our Upcoming PAPERI Webinar Series session
Positive
Jun 23, 2025, 17:34
Jasmine Kamboj: Enjoying the Support of Senator Klobuchar’s Office on Many Levels
Blog
Jun 23, 2025, 17:25
Dato' Dr Saunthari Somasundaram: The National Cancer Congress 2025 Has Been Nothing Short of Inspiring
Career
Jun 23, 2025, 17:16
Mercy Sopuruchi Agu Has Been Appointed Patient Navigator and Fundraising Lead at Project PINK BLUE
Blog
Jun 23, 2025, 17:07
Sebastian Szmit: Proud of My Team at ESC Cardio Oncology 2025
Positive
Jun 23, 2025, 16:55
Paul Hakimata: How Memorial Healthcare System is Becoming a Destination for Cancer Care
Science
Jun 23, 2025, 16:36
New Research on Targeted Axillary Radiation in Early Breast Cancer by Ahmed Orabi et al.
Science
Jun 23, 2025, 15:18
Myeloma Paper of the Day, June 23rd, suggested by Robert Orlowski
Oncolibrary
Jun 23, 2025, 13:51
Press Release: Zanzalintinib Plus Atezolizumab Improves Survival in Refractory Metastatic Colorectal Cancer: STELLAR-303 Results
Insight
Jun 23, 2025, 11:20
Goutham Sunny Highlighted PANOVA-3 Phase III Trial on TTFields Plus Chemotherapy in Locally Advanced Pancreatic Cancer
Insight
Jun 23, 2025, 11:18
Zihai Li: Are NK Cells Friends or Foes In Cancer Immunotherapy?